<p>PetMed Express（納斯達克代碼：PETS - 獲取免費報告）預計將在 2026 年 12 月 24 日星期三市場開盤前發佈其第二季度財報。分析師預計該公司將在本季度宣佈每股收益為 0.04 美元。各方可以查看公司即將發佈的 2026 年第二季度財報中的信息，以獲取關於定於 2025 年 12 月 23 日星期二東部時間凌晨 12:00 的電話會議的最新細節。</p>
<p>獲取 <strong>PetMed Express</strong> 警報：</p>
<ul>
<li>Petco Health &amp; Wellness 是否因每股收益超預期而擺脱困境？</li>
</ul>
<p>PetMed Express（納斯達克代碼：PETS - 獲取免費報告）最近在 2023 年 10 月 14 日星期二發佈了季度財報。該公司報告本季度每股收益為（0.56 美元），低於分析師一致預期的 0.04 美元，差距為（0.60 美元）。該季度的營業收入為 4647 萬美元。PetMed Express 的淨利潤率為負 2.76%，股本回報率為負 6.76%。分析師平均預計 PetMed Express 在當前財政年度的每股收益為 0 美元，下一財政年度的每股收益也為 0 美元。</p>
<h2>PetMed Express 股票表現</h2>
<p>納斯達克：PETS 週五開盤價為 3.65 美元。該股票的 50 日移動平均價格為 2.34 美元，200 日移動平均價格為 2.89 美元。該股票的市值為 7800 萬美元，市盈率為-12.17，貝塔值為 0.75。PetMed Express 的 1 年最低價為 1.57 美元，1 年最高價為 5.58 美元。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>這裏有一隻不在困境中的寵物股票</li>
</ul>
<p>PETS 曾是多份研究分析報告的主題。Zacks Research 在 2023 年 9 月 29 日的報告中將 PetMed Express 的評級從 “強烈賣出” 上調至 “持有”。華爾街 Zen 在 2023 年 10 月 18 日的研究報告中將 PetMed Express 的評級從 “持有” 下調至 “賣出”。最後，Weiss Ratings 在 2023 年 10 月 8 日的研究報告中重申了對 PetMed Express 的 “賣出（d）” 評級。一位研究分析師對該股票給予了 “持有” 評級，另外兩位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “賣出”，共識目標價為 3.20 美元。</p>
<p><strong>查看我們對 PetMed Express 的最新分析</strong></p>
<h2>PetMed Express 的機構交易</h2>
<ul>
<li>這 5 只寵物護理股票中的一隻可能成為下一個空頭擠壓</li>
</ul>
<p>一些大型投資者最近對 PETS 的持倉進行了調整。高盛集團在第一季度將其在 PetMed Express 的持股增加了 59.3%。高盛集團目前擁有 33209 股該公司的股票，價值 139000 美元，此前在上個季度購買了 12360 股。Occudo Quantitative Strategies LP 在第二季度獲得了 PetMed Express 的新頭寸，價值 51000 美元。Bridgeway Capital Management LLC 在第二季度將其在 PetMed Express 的持股增加了 96.2%。Bridgeway Capital Management LLC 目前擁有 40800 股該公司的股票，價值 135000 美元，此前在此期間購買了 20000 股。Oxford Asset Management LLP 在第二季度購買了 PetMed Express 的新頭寸，價值 55000 美元。最後，Dimensional Fund Advisors LP 在第三季度將其在 PetMed Express 的持股增加了 5.4%。Dimensional Fund Advisors LP 目前擁有 481517 股該公司的股票，價值 1209000 美元，此前在上個季度購買了 24624 股。機構投資者和對沖基金持有該公司 73.33% 的股票。</p>
<h2>關於 PetMed Express</h2>
<p>（獲取免費報告）</p>
<p>PetMed Express, Inc 及其子公司在美國經營寵物藥房。該公司銷售處方和非處方寵物藥物、健康產品及其他狗、貓和馬的用品。它提供非處方藥物和用品，如跳蚤和蜱蟲控制產品、骨骼和關節護理產品、維生素、零食、營養補充品、衞生產品和家庭寵物用品；以及處方藥物，包括心絲蟲預防藥、跳蚤和蜱蟲預防藥、關節炎、皮膚炎、甲狀腺、糖尿病、止痛藥、心臟/血壓藥物及其他特殊藥物，以及仿製藥替代品。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 PetMed Express 更好</li>
<li>掌握紀律：克服交易中的情緒挑戰</li>
<li>高通的巨型反彈有個隱患——這隻股票能否繼續上漲？</li>
<li>如何投資藍籌股</li>
<li>博通股票暴跌 20%——但華爾街認為它將飆升至 500 美元</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 PetMed Express 嗎？</h2>
<p>在你考慮 PetMed Express 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 PetMed Express 並不在名單上。</p>
<p>雖然 PetMed Express 目前在分析師中被評為 “賣出”，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PETS

<p>PetMed Express（納斯達克代碼：PETS）定於 2026 年 12 月 24 日星期三市場開盤前發佈其 2026 年第二季度財報。分析師預計每股收益為 0.04 美元。該公司此前報告 2026 年第一季度每股虧損 0.56 美元。該股票的共識評級為 “賣出”，目標價為 3.20 美元。機構投資者持有該公司 73.33% 的股份。PetMed Express 在美國作為一家寵物藥房運營，提供處方和非處方藥物及寵物用品</p>

<p>PetMed Express (NASDAQ:PETS - Get Free Report) is projected to release its Q2 2026 results before the market opens on Wednesday, December 24th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. Parties may review the information on the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, December 23, 2025 at 12:00 AM ET.</p>
<div class="lb-trans"><p>PetMed Express（納斯達克代碼：PETS - 獲取免費報告）預計將在 2026 年 12 月 24 日星期三市場開盤前發佈其第二季度財報。分析師預計該公司將在本季度宣佈每股收益為 0.04 美元。各方可以查看公司即將發佈的 2026 年第二季度財報中的信息，以獲取關於定於 2025 年 12 月 23 日星期二東部時間凌晨 12:00 的電話會議的最新細節。</p>
</div><p>Get <strong>PetMed Express</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PetMed Express</strong> 警報：</p>
</div><ul>
<li>Is Petco Health &amp; Wellness Out of the Doghouse on an EPS beat?</li>
</ul>
<div class="lb-trans"><ul>
<li>Petco Health &amp; Wellness 是否因每股收益超預期而擺脱困境？</li>
</ul>
</div><p>PetMed Express (NASDAQ:PETS - Get Free Report) last posted its quarterly earnings results on Tuesday, October 14th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.60). The business had revenue of $46.47 million during the quarter. PetMed Express had a negative net margin of 2.76% and a negative return on equity of 6.76%. On average, analysts expect PetMed Express to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>PetMed Express（納斯達克代碼：PETS - 獲取免費報告）最近在 2023 年 10 月 14 日星期二發佈了季度財報。該公司報告本季度每股收益為（0.56 美元），低於分析師一致預期的 0.04 美元，差距為（0.60 美元）。該季度的營業收入為 4647 萬美元。PetMed Express 的淨利潤率為負 2.76%，股本回報率為負 6.76%。分析師平均預計 PetMed Express 在當前財政年度的每股收益為 0 美元，下一財政年度的每股收益也為 0 美元。</p>
</div><h2>PetMed Express Stock Performance</h2>
<div class="lb-trans"><h2>PetMed Express 股票表現</h2>
</div><p>NASDAQ:PETS opened at $3.65 on Friday. The stock has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.89. The stock has a market capitalization of $78.00 million, a price-to-earnings ratio of -12.17 and a beta of 0.75. PetMed Express has a 1 year low of $1.57 and a 1 year high of $5.58.</p>
<div class="lb-trans"><p>納斯達克：PETS 週五開盤價為 3.65 美元。該股票的 50 日移動平均價格為 2.34 美元，200 日移動平均價格為 2.89 美元。該股票的市值為 7800 萬美元，市盈率為-12.17，貝塔值為 0.75。PetMed Express 的 1 年最低價為 1.57 美元，1 年最高價為 5.58 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Here’s The One Pet Stock That’s Not in the Doghouse</li>
</ul>
<div class="lb-trans"><ul>
<li>這裏有一隻不在困境中的寵物股票</li>
</ul>
</div><p>PETS has been the subject of a number of research analyst reports. Zacks Research upgraded shares of PetMed Express from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Monday, September 29th. Wall Street Zen lowered shares of PetMed Express from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, October 18th. Finally, Weiss Ratings reiterated a &#34;sell (d)&#34; rating on shares of PetMed Express in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Sell&#34; and a consensus price target of $3.20.</p>
<div class="lb-trans"><p>PETS 曾是多份研究分析報告的主題。Zacks Research 在 2023 年 9 月 29 日的報告中將 PetMed Express 的評級從 “強烈賣出” 上調至 “持有”。華爾街 Zen 在 2023 年 10 月 18 日的研究報告中將 PetMed Express 的評級從 “持有” 下調至 “賣出”。最後，Weiss Ratings 在 2023 年 10 月 8 日的研究報告中重申了對 PetMed Express 的 “賣出（d）” 評級。一位研究分析師對該股票給予了 “持有” 評級，另外兩位則給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “賣出”，共識目標價為 3.20 美元。</p>
</div><p><strong>View Our Latest Analysis on PetMed Express</strong></p>
<div class="lb-trans"><p><strong>查看我們對 PetMed Express 的最新分析</strong></p>
</div><h2>Institutional Trading of PetMed Express</h2>
<div class="lb-trans"><h2>PetMed Express 的機構交易</h2>
</div><ul>
<li>One of these 5 Pet Care Stocks Can Be the Next Short Squeeze</li>
</ul>
<div class="lb-trans"><ul>
<li>這 5 只寵物護理股票中的一隻可能成為下一個空頭擠壓</li>
</ul>
</div><p>A number of large investors have recently made changes to their positions in PETS. Goldman Sachs Group Inc. lifted its holdings in PetMed Express by 59.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 33,209 shares of the company's stock valued at $139,000 after purchasing an additional 12,360 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in PetMed Express in the 2nd quarter valued at $51,000. Bridgeway Capital Management LLC lifted its stake in shares of PetMed Express by 96.2% during the 2nd quarter. Bridgeway Capital Management LLC now owns 40,800 shares of the company's stock worth $135,000 after purchasing an additional 20,000 shares during the period. Oxford Asset Management LLP purchased a new position in shares of PetMed Express during the 2nd quarter worth $55,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of PetMed Express by 5.4% during the third quarter. Dimensional Fund Advisors LP now owns 481,517 shares of the company's stock worth $1,209,000 after purchasing an additional 24,624 shares during the last quarter. Institutional investors and hedge funds own 73.33% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投資者最近對 PETS 的持倉進行了調整。高盛集團在第一季度將其在 PetMed Express 的持股增加了 59.3%。高盛集團目前擁有 33209 股該公司的股票，價值 139000 美元，此前在上個季度購買了 12360 股。Occudo Quantitative Strategies LP 在第二季度獲得了 PetMed Express 的新頭寸，價值 51000 美元。Bridgeway Capital Management LLC 在第二季度將其在 PetMed Express 的持股增加了 96.2%。Bridgeway Capital Management LLC 目前擁有 40800 股該公司的股票，價值 135000 美元，此前在此期間購買了 20000 股。Oxford Asset Management LLP 在第二季度購買了 PetMed Express 的新頭寸，價值 55000 美元。最後，Dimensional Fund Advisors LP 在第三季度將其在 PetMed Express 的持股增加了 5.4%。Dimensional Fund Advisors LP 目前擁有 481517 股該公司的股票，價值 1209000 美元，此前在上個季度購買了 24624 股。機構投資者和對沖基金持有該公司 73.33% 的股票。</p>
</div><h2>About PetMed Express</h2>
<div class="lb-trans"><h2>關於 PetMed Express</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.</p>
<div class="lb-trans"><p>PetMed Express, Inc 及其子公司在美國經營寵物藥房。該公司銷售處方和非處方寵物藥物、健康產品及其他狗、貓和馬的用品。它提供非處方藥物和用品，如跳蚤和蜱蟲控制產品、骨骼和關節護理產品、維生素、零食、營養補充品、衞生產品和家庭寵物用品；以及處方藥物，包括心絲蟲預防藥、跳蚤和蜱蟲預防藥、關節炎、皮膚炎、甲狀腺、糖尿病、止痛藥、心臟/血壓藥物及其他特殊藥物，以及仿製藥替代品。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than PetMed Express</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 PetMed Express 更好</li>
<li>掌握紀律：克服交易中的情緒挑戰</li>
<li>高通的巨型反彈有個隱患——這隻股票能否繼續上漲？</li>
<li>如何投資藍籌股</li>
<li>博通股票暴跌 20%——但華爾街認為它將飆升至 500 美元</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>忘掉芯片：AI 反彈的 4 個工業投資機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVUUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=PETS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PetMed Express Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 PetMed Express 嗎？</h2>
</div><p>Before you consider PetMed Express, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 PetMed Express 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前購買……而 PetMed Express 並不在名單上。</p>
</div><p>While PetMed Express currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PetMed Express 目前在分析師中被評為 “賣出”，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PetMed Express (PETS) 預計將在週三公佈財報